Zepbound (mirikizumab) is a monoclonal antibody designed to treat moderate to severe ulcerative colitis (UC) in adults. It works by specifically targeting interleukin-23p19, a protein believed to play a key role in the inflammatory process driving UC. By blocking this protein, Zepbound aims to reduce inflammation in the colon and alleviate symptoms.
Administered as a subcutaneous injection, Zepbound offers patients a self-administered treatment option following initial doses administered by a healthcare professional.
Clinical trials have demonstrated its efficacy in achieving clinical remission and endoscopic improvement in individuals with UC who haven't responded adequately to conventional or biologic therapies.
Common side effects may include nasopharyngitis (common cold), arthralgia (joint pain), and injection site reactions. Zepbound represents a potential new therapeutic avenue for those struggling to manage their UC.